A phase I study of concurrent chemoradiotherapy and cetuximab for locally advanced esophageal cancer

Cecilie Holländer; Lene Bæksgaard Jensen; Morten Sorensen; Per Albertsson; Lars Damstrup; Ulrik Lassen

A phase I study of concurrent chemoradiotherapy and cetuximab for locally advanced esophageal cancer

Cecilie Holländer, Lene Bæksgaard Jensen, Morten Sorensen, Per Albertsson, Lars Damstrup, Ulrik Lassen

4 Citations (Scopus)

Abstract

To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of concurrent chemoradiotherapy and cetuximab in patients with non-resectable locally advanced esophageal cancer.

Original language	English
Journal	Anticancer Research
Volume	32
Issue number	9
Pages (from-to)	4019-23
Number of pages	5
ISSN	0250-7005
Publication status	Published - 2012

Keywords

Adult
Aged
Antibodies, Monoclonal
Antineoplastic Combined Chemotherapy Protocols
Chemoradiotherapy
Dose-Response Relationship, Drug
Drug Administration Schedule
Esophageal Neoplasms
Female
Humans
Male
Middle Aged
Organoplatinum Compounds
Tegafur
Uracil

Cite this

@article{76c753bea0d94b34af449f338562c8dd,

title = "A phase I study of concurrent chemoradiotherapy and cetuximab for locally advanced esophageal cancer",

abstract = "To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of concurrent chemoradiotherapy and cetuximab in patients with non-resectable locally advanced esophageal cancer.",

keywords = "Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Chemoradiotherapy, Dose-Response Relationship, Drug, Drug Administration Schedule, Esophageal Neoplasms, Female, Humans, Male, Middle Aged, Organoplatinum Compounds, Tegafur, Uracil",

author = "Cecilie Holl{\"a}nder and Jensen, {Lene B{\ae}ksgaard} and Morten Sorensen and Per Albertsson and Lars Damstrup and Ulrik Lassen",

year = "2012",

language = "English",

volume = "32",

pages = "4019--23",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "9",

}

TY - JOUR

T1 - A phase I study of concurrent chemoradiotherapy and cetuximab for locally advanced esophageal cancer

AU - Holländer, Cecilie

AU - Jensen, Lene Bæksgaard

AU - Sorensen, Morten

AU - Albertsson, Per

AU - Damstrup, Lars

AU - Lassen, Ulrik

PY - 2012

Y1 - 2012

N2 - To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of concurrent chemoradiotherapy and cetuximab in patients with non-resectable locally advanced esophageal cancer.

AB - To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of concurrent chemoradiotherapy and cetuximab in patients with non-resectable locally advanced esophageal cancer.

KW - Adult

KW - Aged

KW - Antibodies, Monoclonal

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Chemoradiotherapy

KW - Dose-Response Relationship, Drug

KW - Drug Administration Schedule

KW - Esophageal Neoplasms

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Organoplatinum Compounds

KW - Tegafur

KW - Uracil

M3 - Journal article

C2 - 22993353

SN - 0250-7005

VL - 32

SP - 4019

EP - 4023

JO - Anticancer Research

JF - Anticancer Research

IS - 9

ER -

A phase I study of concurrent chemoradiotherapy and cetuximab for locally advanced esophageal cancer

Abstract

Keywords

Fingerprint

Cite this